In fact, CEA is expressed in over 90% of PDA patients, but it is poorly immunogenic because of immune tolerance; thus, the idea was to set a vaccination strategy based on the identification of CEA-related neoantigens. This evidence concerns the gene CEACAM5 and Patent ductus arteriosus.